Abstract:Abstract Background Several studies including ours reported the detrimental effects of extracellular tau oligomers (ex‐oTau) on glutamatergic synaptic transmission and plasticity. Astrocytes greatly internalize ex‐oTau thus contributing to their clearance. However, glial cell engulfment of oTau leads to alteration of neuro/gliotransmitter handling that negatively affects synaptic function. We previously reported that amyloid precursor protein (APP) is required for oTau internalization in astrocytes but the molecular mechanisms underlying this phenomenon has not been clearly identified yet. Here we investigated the role of glypican 4 (GPC4), a member of the large family of heparan sulfate proteoglycans that are membrane glycoproteins highly expressed in astrocytes playing a critical role in protein trafficking through the plasma membrane. Method The role of GPC4 in ex‐oTau accumulation in astrocytes and the resulting synaptotoxic action were studied in in vitro and ex‐vivo models obtained from wild‐type C57/bl6 and transgenic mice in which either APP was knocked‐out or it contained the non‐phosphorylatable amino acid alanine replacing threonine 688 (APP TA mice). In these experimental models we performed immunofluorescence analyses, Western blot and real‐time PCR experiments, confocal Ca 2+ imaging, high‐pressure liquid chromatography, FM1‐43 imaging, electrophysiological recordings and Chromatin immunoprecipitation assays. Result Treatment of cultured astrocytes with a specific anti‐GPC4 antibody significantly reduced oTau internalization in astrocytes and prevented oTau‐induced alterations of intracellular Ca 2+ signaling and gliotransmitter release. As such, anti‐GPC4 treatment spared neurons from the astrocyte‐mediated synaptotoxic action of ex‐oTau. Specifically, after counteracting the interaction between ex‐oTau and GPC4 no significant decreases in synaptic vesicular release and synaptic protein expression were observed in neurons co‐cultured with astrocytes following exposure to ex‐oTau. The latter also failed to inhibit hippocampal LTP at CA3‐CA1 synapses. Of note, we found that the expression of GPC4 depended on APP and, in particular, on its C‐terminal domain, AICD, generated by γ‐secretase‐dependent cleavage of APP, that can bind Gpc4 promoter. Accordingly, GPC4 expression was significantly reduced in both APP‐KO ad APP TA mice, and ex‐oTau did not exert any significant detrimental action on synaptic function in APP‐KO mice. Conclusion Collectively, our data indicate that GPC4 expression is APP/AICD‐dependent, it mediates oTau accumulation in astrocytes and the resulting synaptotoxic effects.

Astrocyte-secreted glypican-4 drives APOE4-dependent tau pathology

Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation

APP/AICD‐dependent expression of Glypican 4 mediates accumulation of tau oligomers in astrocytes and their synaptotoxic action

ApoE4 expression disrupts tau uptake, trafficking, and clearance in astrocytes

Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits

Intracellular accumulation of tau oligomers in astrocytes and their synaptotoxic action rely on Amyloid Precursor Protein Intracellular Domain-dependent expression of Glypican-4

Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease

The influence of APOEε4 on the pTau interactome in sporadic Alzheimer's disease

The relationship between ApoE4 and lipid dysregulation in glia of the PS19 mouse model of tauopathy

Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia

Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer's disease

CSF tau is associated with impaired cortical plasticity, cognitive decline and astrocyte survival only in APOE4-positive Alzheimer’s disease

Apolipoprotein E4 Causes Age- And Tau-Dependent Impairment Of Gabaergic Interneurons, Leading To Learning And Memory Deficits In Mice

Intracerebral Expression of AAV-APOE4 Is Not Sufficient to Alter Tau Burden in Two Distinct Models of Tauopathy

APOE4 impairs the microglial response in Alzheimer's disease by inducing TGF-mediated checkpoints

APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints

APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta

Neuronal ApoE4 stimulates C/EBPβ activation, promoting Alzheimer’s disease pathology in a mouse model

APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles

APOE4 Impairs Microglia ‐ Astrocyte Crosstalk in Alzheimer Disease

ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy